Andrew King, Gail Masterton, Bridget Gunson, Simon Olliff, Doris Redhead, Kamarjit Mangat, Gabriel Oniscu, Peter Hayes, Dhiraj Tripathi – 4 February 2011 – The role of transjugular intrahepatic portosystemic shunt (TIPS) insertion in managing the complications of portal hypertension is well established, but its utility in patients who have previously undergone liver transplantation is not well documented. Twenty‐two orthotopic liver transplantation (OLT) patients and 44 nontransplant patients (matched controls) who underwent TIPS were analyzed.

Cristiano Quintini, Giuseppe D'Amico, Chase Brown, Federico Aucejo, Koji Hashimoto, Dympna M. Kelly, Bijan Eghtesad, Mark Sands, John J. Fung, Charles M. Miller – 4 February 2011 – Refractory ascites (RA) is a challenging complication after orthotopic liver transplantation. Its treatment consists of the removal of the precipitating factors. When the etiology is unknown, supportive treatment can be attempted. In severe cases, transjugular intrahepatic portosystemic shunts, portocaval shunts, and liver retransplantation have been used with marginal results.

Andreas Pfannkuche, Katrin Büther, Juliane Karthe, Marion Poenisch, Ralf Bartenschlager, Mirko Trilling, Hartmut Hengel, Dieter Willbold, Dieter Häussinger, Johannes Georg Bode – 31 January 2011 – Hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide and establishes a persistent infection in more than 60% of infected individuals. This high frequency of persistent infection indicates that HCV has evolved efficient strategies to interfere with the adaptive and innate immune response and to occupy and use host cell infrastructure.

Maria Stepanova, Zobair M. Younossi – 31 January 2011

Waka Ohishi, Saeko Fujiwara, John B. Cologne, Gen Suzuki, Masazumi Akahoshi, Nobuo Nishi, Masataka Tsuge, Kazuaki Chayama – 31 January 2011 – In cohort studies of atomic bomb survivors and Mayak nuclear facility workers, radiation‐associated increases in liver cancer risk were observed, but hepatitis B virus (HBV) and hepatitis C virus (HCV) infections were not taken strictly into account. We identified 359 hepatocellular carcinoma (HCC) cases between 1970 and 2002 in the cohort of atomic bomb survivors and estimated cumulative incidence of HCC by radiation dose.

Liang Shen – 31 January 2011

Peter J. Lewindon, Grant A. Ramm – 31 January 2011

Hanaa Nafady‐Hego, Hamed Elgendy, Walid El Moghazy, Kazuhiko Fukuda, Shinji Uemoto – 31 January 2011 – Infection after pediatric living donor liver transplantation (LDLT) is a major cause of morbidity and mortality. Here, we sought to determine the incidence, timing, location, and risk factors for bacterial and fungal infections. We retrospectively investigated infection for 3 postoperative months in 345 consecutive pediatric patients (56.2% were females) who underwent primary LDLT at Kyoto University Hospital, Japan.

Nicole E. Scouras, Takashi Matsusaki, Charles D. Boucek, Cynthia Wells, Erik A. Cooper, Raymond M. Planinsic, Erin A. Sullivan, Christian A. Bermudez, Yoshiya Toyoda, Tetsuro Sakai – 28 January 2011 – End‐stage liver disease with severe portopulmonary hypertension (PPHTN), which is refractory to vasodilator therapies, is a contraindication for isolated liver transplantation (LT) because of the high mortality rate.

See Ching Chan, Chung Mau Lo, Kelvin K.C. Ng, Irene O.L. Ng, Boon Hun Yong, Sheung Tat Fan – 28 January 2011 – The middle hepatic vein may be included in right liver living donor liver transplantation (LDLT) to optimize hepatic venous outflow. We studied the graft's ability to relieve portal hypertension and accommodate portal hyperperfusion with portal manometry and ultrasonic flowmetry. Surgical outcomes with respect to portal hemodynamometry were also investigated.